A Peptide Spray Improved Diabetic Foot Infections. The Bacteria Told a More Complicated Story
A randomized trial found that topical peceleganan improved short-term clinical response in infected diabetic foot ulcers, while overall bacterial eradication remained uncertain.
A topical peptide spray called peceleganan improved the short-term clinical response of mild-to-moderate diabetic foot ulcer infections in a new randomized trial. That sounds like the clean result researchers have wanted from antimicrobial peptides for years.
Then you look at the cultures.
Across the full study population, bacterial eradication was numerically better with the peptide, but the differences were not statistically significant. A drug-resistant subgroup did show a significant advantage. The useful reading is therefore neither “breakthrough antibiotic replacement” nor “failed experiment.” Peceleganan may be doing something clinically valuable, but the newest paper leaves important questions about what it clears, how durable the benefit is, and where it belongs in real wound care.
The new trial, without the victory lap
The study, published in the Journal of Diabetes in July 2026, enrolled people with mildly to moderately infected diabetic foot ulcers at four tertiary hospitals. Participants were randomized to PL-5 spray or placebo. Both groups received standardized debridement, the removal of dead or infected tissue that remains a basic part of ulcer care.
The design matters. It was multicenter, randomized, double-blind, and placebo-controlled, which is stronger than the open-label comparisons that often dominate early wound-treatment research. The primary endpoint was clinical response one day after treatment ended, referred to as EOT1.
PL-5 produced a significantly better clinical response at that point. The accessible abstract reports a p value below 0.05 but does not provide the numerical response rates or the total number randomized. We are not going to reverse-engineer those missing numbers from percentages. Until the complete tables are available, the honest conclusion is that the trial met its short-term clinical endpoint, while the size and precision of that benefit remain difficult to judge from the abstract alone.
That missing detail is not clerical trivia. “Clinical response” can combine visible changes such as less redness, drainage, swelling, or pain. Those outcomes matter to patients and clinicians. But they are not interchangeable with complete infection clearance, ulcer closure, avoidance of amputation, or freedom from recurrence.
The microbiology is where the story gets interesting
At EOT1, overall microbiological eradication was 57.89% with PL-5 and 33.33% with placebo. Seven days later, the rates were 64.71% and 40.00%. Both comparisons favored the peptide numerically, but neither reached statistical significance.
The resistant-bacteria subgroup looked more encouraging. Clearance at EOT1 was 71.43% with PL-5 versus 50% with placebo, a statistically significant difference. That signal deserves attention because antimicrobial resistance is not an abstract future risk. The World Health Organization reported in July 2026 that roughly one in six laboratory-confirmed bacterial infections worldwide in 2023 were resistant to antibiotics.
Still, a subgroup is not the whole trial. The abstract does not disclose the subgroup denominators or enough detail to tell us how stable the estimate is. A percentage can look precise even when it comes from a small number of cultures. We also cannot tell from the abstract whether this analysis was prespecified, which organisms drove the result, or whether resistant pathogens returned after follow-up.
So the rehook is real but narrow: PL-5 may be particularly useful against resistant wound bacteria, while broad pathogen clearance is not yet established.
What is peceleganan supposed to do?
Peceleganan, also called PL-5, is an antimicrobial peptide developed as a topical spray. Antimicrobial peptides are short amino-acid chains that can disrupt microbial membranes. Instead of relying on the same single enzyme or metabolic pathway targeted by many conventional antibiotics, a membrane-active peptide can damage the physical integrity of a bacterium.
That mechanism is attractive for two reasons. First, topical delivery can create a high concentration at the wound while limiting systemic exposure. Second, membrane disruption may make some familiar resistance routes harder to use. “Harder” is the important word. No antimicrobial is resistance-proof, and laboratory activity does not guarantee durable clinical performance inside a wound full of exudate, dead tissue, mixed organisms, and biofilm.
Biofilms are especially troublesome. Bacteria embedded in a protective matrix can behave very differently from free-floating organisms in a dish. A 2026 PLOS One study tested PL-5 inside a red-light-responsive liposome against MRSA and biofilms. The system improved antimicrobial activity in vitro, but it is a separate experimental formulation, not evidence that the spray used in the diabetic-foot trial breaks down biofilm in patients.
This is not PL-5's first human test
The new study sits inside a longer clinical program.
A Phase IIb randomized trial published in the Annals of Surgery included 220 people with wound infections and compared several PL-5 concentrations with silver sulfadiazine. Clinical efficacy rates favored PL-5, blood concentrations were undetectable in the pharmacokinetic analysis, and no severe treatment-related adverse event was reported. The trial was open-label, which makes subjective clinical assessments more vulnerable to bias.
A larger Phase 3 trial published in JAMA Network Open in 2024 randomized 570 adults with secondary open-wound infections across 37 hospitals in China. On day eight, clinical efficacy was reported in 90.4% of the 2% peceleganan group and 78.7% of the 1% silver sulfadiazine group.
But again, the cultures complicated the headline. Day-eight bacterial clearance was 24.0% with peceleganan and 46.0% with silver sulfadiazine. The investigators concluded that the spray had satisfactory clinical efficacy while bacterial clearance remained uncertain.
That earlier result is a useful guardrail for reading the 2026 trial. A wound can look clinically better before its culture turns negative. Debridement itself can improve local conditions. Inflammation can fall without every organism disappearing. Those possibilities do not make clinical improvement meaningless, but they prevent us from using it as shorthand for microbiological cure.
Safety looked reassuring, within a short window
Adverse events occurred in 24.24% of participants receiving PL-5 and 33.33% receiving placebo in the new trial. The difference was not statistically significant, and no serious drug-related adverse events were reported.
That is reassuring as far as it goes. A topical product with limited systemic absorption could have practical advantages for selected patients, particularly when kidney function, drug interactions, or systemic antibiotic toxicity complicate treatment. But this study does not establish long-term safety, and it does not show that systemic therapy can be skipped when the infection extends beyond the superficial wound.
Diabetic foot infection can progress quickly. Fever, spreading redness, tissue death, loss of blood flow, deep abscess, exposed bone, or suspected osteomyelitis changes the problem entirely. A topical investigational spray is not a substitute for urgent assessment, imaging, surgery, revascularization, or systemic antibiotics when those are indicated.
The limitation hidden in the word “mild”
The trial studied mild-to-moderate infections. That is a clinically important population, but it is also the setting where debridement, pressure off-loading, blood-glucose management, vascular assessment, and careful follow-up may do much of the heavy lifting.
The accessible report does not give us ulcer-closure rates, time to healing, amputations, recurrence, hospitalizations, or long-term antibiotic use. It also does not establish superiority to an active standard antibiotic. The control was placebo on top of standardized debridement, not a head-to-head comparison with a guideline-selected antimicrobial regimen.
One author listed in the paper is affiliated with Jiangsu Protelight Pharmaceutical Company, the company associated with PL-5. Industry participation is common in drug development and does not invalidate a trial. It does make complete protocol access, prespecified analyses, and independent replication more important.
There is also a broader evidence problem. A Cochrane review of topical antimicrobials for diabetic foot ulcers found the literature limited by small, short, and often poorly designed studies. This new randomized trial improves that landscape, but one positive clinical endpoint does not erase decades of uncertainty.
What it means for antimicrobial peptides
Peceleganan is one of the clearer tests of the antimicrobial-peptide idea because it has moved beyond petri dishes and mouse models into randomized human studies. That alone separates it from many compounds sold online under the peptide label.
The latest trial adds three useful pieces of information. A blinded study can detect short-term clinical benefit over placebo when both groups receive debridement. Overall culture clearance remains unresolved. A resistant-pathogen subgroup may be where the drug has its strongest value, but that finding needs larger numbers and transparent follow-up.
The next decisive trial should make the endpoints harder to blur. It should report the absolute clinical response rates, pathogen-specific clearance, resistant-subgroup denominators, ulcer healing, recurrence, systemic antibiotic exposure, amputations, and adverse events over months rather than days. A comparison against modern standard care would tell clinicians far more than another placebo-controlled snapshot.
The Oria take
This is a credible human peptide study, not a wellness extrapolation. It is also not a reason to buy an unverified “antimicrobial peptide spray” or treat an infected diabetic foot at home.
PL-5 looks most interesting as a locally delivered drug candidate that could complement debridement and, potentially, reduce reliance on systemic antibiotics in carefully selected infections. The resistant-bacteria signal is worth following. The mismatch between clinical improvement and overall bacterial eradication is equally important.
Good peptide reporting has to hold both facts at once. The spray helped by the trial's primary clinical measure. It has not yet proved that it reliably clears infection, heals ulcers faster, prevents amputations, or replaces established treatment.
Sources
Evidence grade: B-. A multicenter, randomized, double-blind, placebo-controlled human trial met its short-term clinical endpoint, supported by an earlier randomized development program. The grade is reduced because the accessible report omits key sample and effect-size details, overall microbiological eradication was not significant, the resistant-pathogen result is a subgroup finding, and long-term healing and limb outcomes are unknown.
Medical disclaimer: This article is for education only and is not medical advice. Diabetic foot ulcers and suspected infections require prompt evaluation by a qualified clinician; delays can lead to tissue loss, bone infection, sepsis, or amputation. Peceleganan is discussed as an investigational therapy and should not be sourced or used outside appropriate regulatory and clinical channels. Oria exists to make peptide evidence easier to evaluate, not to replace individualized diagnosis or treatment.
Build Your Personalised Protocol
Turn your research into a personalised supplementation protocol with the BioStack Generator.